|
|
Sold Out
Book Categories |
| Ch. 1 | Introduction | 1 |
| Radiobiology, Radiation Physics, and Dosimetry | ||
| Ch. 2 | Medical Internal Dosimetry for High-Dose Radionuclide Therapies | 7 |
| Ch. 3 | Radiolabeled Antibody Tumor Dosimetry | 21 |
| Ch. 4 | Radiobiology and Radioimmunotherapy: Implications for Clinical Applications | 33 |
| Radiochemistry of Therapeutic Radionuclides | ||
| Ch. 5 | Radiochemistry of Therapeutic Radionuclides | 47 |
| Ch. 6 | Advanced Methods for Radiolabeling Monoclonal Antibodies with Therapeutic Radionuclides | 63 |
| Ch. 7 | Antibody Radiolabeling with Isotopes of Rhenium | 77 |
| Targeting, Pharmacokinetics, and Experimental Radioimmunotherapy | ||
| Ch. 8 | Pharmacokinetics of Antibodies and their Radiolabels | 89 |
| Ch. 9 | Development of Cancer Radioimmunotherapy and its Potential Use as an Adjuvant Treatment | 101 |
| Ch. 10 | Experimental Radioimmunotherapy and Methods to Increase Therapeutic Efficacy | 115 |
| Clinical Radioimmunotherapy | ||
| Ch. 11 | Overview of Obstacles and Opportunities for Radioimmunotherapy of Cancer | 141 |
| Ch. 12 | Radioimmunotherapy of Ovarian Cancer | 155 |
| Ch. 13 | Radioimmunotherapy of Colorectal Cancer | 173 |
| Ch. 14 | Radioimmunotherapy in the Treatment of Metastatic Breast Cancer: An Overview | 189 |
| Ch. 15 | Radioimmunotherapy of CNS Malignant Gliomas by Direct Intralesional Injection of Specific [superscript 131]I Radiolabeled Monoclonal Antibodies | |
| Ch. 16 | Treatment of B-Lymphocyte Malignancies with [superscript 131]I-Lym-1-and [superscript 67]Cu-2IT-BAT-Lym-1 and Opportunities for Improvement | 217 |
| Ch. 17 | Treatment of Relapsed B Cell Lymphomas with High-Dose Radioimmunotherapy and Bone Marrow Transplantation | 229 |
| New Strategies | ||
| Ch. 18 | Clinical Application of the Avidin-Biotin System for Tumor Targeting | 239 |
| Ch. 19 | Humanization of Monoclonal Antibodies: Molecular Approaches and Applications | 255 |
| Ch. 20 | Human Monoclonal Antibodies: Application in Radioimmunotherapy | 271 |
| Ch. 21 | Cytokine-Based Modalities to Enhance Monoclonal-Antibody-Mediated Tumor Cell Killing | 283 |
| Ch. 22 | Overcoming Dose-Limiting, Antibody-Induced Myelotoxicity | 295 |
| Index | 315 |
| Price | Condition | Delivery | Seller | Action |
| $99.99 | Digital |
| WonderClub |
Login|Complaints|Blog|Games|Digital Media|Souls|Obituary|Contact Us|FAQ
CAN'T FIND WHAT YOU'RE LOOKING FOR? CLICK HERE!!! X
You must be logged in to add to WishlistX
This item is in your Wish List
X
This item is in your Collection
Cancer Therapy: Radiolabeled Antibodies
X
This Item is in Your Inventory
Cancer Therapy: Radiolabeled Antibodies
X
You must be logged in to review the productsX
X
X
Add Cancer Therapy: Radiolabeled Antibodies, Cancer Therapy with Radiolabeled Antibodies explores the most current experimental and clinical advances in the newly emerging field of cancer radioimmunotherapy (RAIT). Providing a multidisciplinary and international context, some of the world's leading , Cancer Therapy: Radiolabeled Antibodies to the inventory that you are selling on WonderClubX
X
Add Cancer Therapy: Radiolabeled Antibodies, Cancer Therapy with Radiolabeled Antibodies explores the most current experimental and clinical advances in the newly emerging field of cancer radioimmunotherapy (RAIT). Providing a multidisciplinary and international context, some of the world's leading , Cancer Therapy: Radiolabeled Antibodies to your collection on WonderClub |